CXO Leader Performance Validates High Prosperity, BD Going Global Trend Unabated, Low-Fee Hong Kong Stock Connect Innovative Drug ETF Everbright (159316) Rose 4.21%

NightAirdropper · 2026-03-25T13:11:47+00:00

The pharmaceutical sector showed strong performance today, with E Fund Innovation Medicine ETF rising 4.21%. Wuxi AppTec forecasted significant growth in revenue and profit for 2025, with CXO enterprises maintaining high prosperity. Meanwhile, domestic innovative pharmaceuticals' overseas transaction deals hit record highs. With valuations retreating to low levels, the outlook remains optimistic, and increased capital inflows are providing support for the sector.

NightAirdropper

2026-03-25 13:11:47

Abstract generation in progress

Gelonghui, March 24 — The pharmaceutical sector is rallying across the board today, with the Hong Kong Stock Connect Innovation Drug ETF E Fund (159316) rising 4.21%, and trading activity remaining lively.

On the news front, leading CXO companies are confirming high industry prosperity through their performance, and the trend of BD going global remains strong.

Leading CXO company WuXi AppTec announced on the evening of the 23rd that by 2025, its revenue will reach 45.46 billion yuan, a 15.8% year-over-year increase, with net profit growing 107.2% YoY. The TIDES business (peptides/oligonucleotides) doubled in growth. The company has abundant orders on hand, and its 2026 performance guidance is optimistic, with revenue growth expected to be between 18% and 22%, and profitability remaining steady, further confirming the high prosperity of CXO enterprises.

BD transactions continue to set records, and the logic of going global deepens: in the first quarter of 2026, the total transaction amount for domestic innovative drug exports reached $57.3 billion, a 135% YoY increase. The export strategy is evolving from “single product licensing” to a new stage of “platform output” and “deeply bundling global rights.”

Industry insiders believe that after previous adjustments, the valuation of the Hong Kong stock innovative drug sector has returned to a relatively low historical range. However, the upward trend driven by “BD going global + commercialization expansion + policy support” remains unchanged, and the sector offers relatively favorable risk-reward.

The Hong Kong Stock Connect Innovation Drug ETF E Fund (159316) saw a net capital inflow of 165 million yuan in the past 20 days, with a latest size of 3.84 billion yuan. Its management fee is 0.15% plus a 0.05% annual custodial fee, making it one of the lowest fee products in the market. The underlying index is 100% focused on core companies in innovative drug R&D, with leading stocks including BeiGene, Innovent Biologics, WuXi Biologics, and Kangfang Biotech.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.